Myeloid-derived suppressor cells in malignant melanoma

Viktor Umansky; Alexandra Sevko; Christoffer Gebhardt; Jochen Utikal

doi:10.1111/ddg.12411

Myeloid-derived suppressor cells in malignant melanoma

Standard

Myeloid-derived suppressor cells in malignant melanoma. / Umansky, Viktor; Sevko, Alexandra; Gebhardt, Christoffer; Utikal, Jochen.

in: J DTSCH DERMATOL GES, Jahrgang 12, Nr. 11, 11.2014, S. 1021-7.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung

Harvard

Umansky, V, Sevko, A, Gebhardt, C & Utikal, J 2014, 'Myeloid-derived suppressor cells in malignant melanoma', J DTSCH DERMATOL GES, Jg. 12, Nr. 11, S. 1021-7. https://doi.org/10.1111/ddg.12411

APA

Umansky, V., Sevko, A., Gebhardt, C., & Utikal, J. (2014). Myeloid-derived suppressor cells in malignant melanoma. J DTSCH DERMATOL GES, 12(11), 1021-7. https://doi.org/10.1111/ddg.12411

Vancouver

Umansky V, Sevko A, Gebhardt C, Utikal J. Myeloid-derived suppressor cells in malignant melanoma. J DTSCH DERMATOL GES. 2014 Nov;12(11):1021-7. https://doi.org/10.1111/ddg.12411

Bibtex

@article{d2b48c7076cd4d399cec20f896399d90,

title = "Myeloid-derived suppressor cells in malignant melanoma",

abstract = "Melanoma is known for its rapid progression, metastasis to distant organs and therapeutic resistance. Despite high melanoma immunogenicity, the results of immunotherapeutic clinical studies are mostly unsatisfactory. One explanation is the development of strong immunosuppression mediated by highly immunosuppressive regulatory leukocytes, in particular, myeloid-derived suppressor cells (MDSCs). These cells were found to be enriched and activated in the melanoma microenvironment, inducing a profound impairment of anti-tumor immune responses and leading to the tumor progression. Therefore, understanding the mechanisms of MDSC generation, migration to the tumor site and activation as well as their targeting is important for the development of novel strategies for effective melanoma immunotherapy. We suggest that such therapeutic approaches should involve the inhibition of MDSC-mediated immunosuppressive melanoma microenvironment combined with other immunologic treatments.",

keywords = "Animals, Cytokines, Humans, Melanoma, Models, Immunological, Myeloid Cells, Skin Neoplasms, Tumor Microenvironment, Journal Article, Review",

author = "Viktor Umansky and Alexandra Sevko and Christoffer Gebhardt and Jochen Utikal",

note = "{\textcopyright} 2014 Deutsche Dermatologische Gesellschaft (DDG). Published by John Wiley & Sons Ltd.",

year = "2014",

month = nov,

doi = "10.1111/ddg.12411",

language = "English",

volume = "12",

pages = "1021--7",

journal = "J DTSCH DERMATOL GES",

issn = "1610-0379",

publisher = "Wiley-Blackwell",

number = "11",

}

RIS

TY - JOUR

T1 - Myeloid-derived suppressor cells in malignant melanoma

AU - Umansky, Viktor

AU - Sevko, Alexandra

AU - Gebhardt, Christoffer

AU - Utikal, Jochen

PY - 2014/11

Y1 - 2014/11

N2 - Melanoma is known for its rapid progression, metastasis to distant organs and therapeutic resistance. Despite high melanoma immunogenicity, the results of immunotherapeutic clinical studies are mostly unsatisfactory. One explanation is the development of strong immunosuppression mediated by highly immunosuppressive regulatory leukocytes, in particular, myeloid-derived suppressor cells (MDSCs). These cells were found to be enriched and activated in the melanoma microenvironment, inducing a profound impairment of anti-tumor immune responses and leading to the tumor progression. Therefore, understanding the mechanisms of MDSC generation, migration to the tumor site and activation as well as their targeting is important for the development of novel strategies for effective melanoma immunotherapy. We suggest that such therapeutic approaches should involve the inhibition of MDSC-mediated immunosuppressive melanoma microenvironment combined with other immunologic treatments.

AB - Melanoma is known for its rapid progression, metastasis to distant organs and therapeutic resistance. Despite high melanoma immunogenicity, the results of immunotherapeutic clinical studies are mostly unsatisfactory. One explanation is the development of strong immunosuppression mediated by highly immunosuppressive regulatory leukocytes, in particular, myeloid-derived suppressor cells (MDSCs). These cells were found to be enriched and activated in the melanoma microenvironment, inducing a profound impairment of anti-tumor immune responses and leading to the tumor progression. Therefore, understanding the mechanisms of MDSC generation, migration to the tumor site and activation as well as their targeting is important for the development of novel strategies for effective melanoma immunotherapy. We suggest that such therapeutic approaches should involve the inhibition of MDSC-mediated immunosuppressive melanoma microenvironment combined with other immunologic treatments.

KW - Animals

KW - Cytokines

KW - Humans

KW - Melanoma

KW - Models, Immunological

KW - Myeloid Cells

KW - Skin Neoplasms

KW - Tumor Microenvironment

KW - Journal Article

KW - Review

U2 - 10.1111/ddg.12411

DO - 10.1111/ddg.12411

M3 - SCORING: Review article

C2 - 25263083

VL - 12

SP - 1021

EP - 1027

JO - J DTSCH DERMATOL GES

JF - J DTSCH DERMATOL GES

SN - 1610-0379

IS - 11

ER -